TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05086770

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Embosphere
Description: Tris-acryl gelatin microspheres (Embosphere Microspheres) are biocompatible and nonresorbable with cell adhesion properties for complete and durable mechanical occlusion.
Study: NCT05168449

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Application
Description: mobile phone applications directed to chronic kidney disease patients to improve their medication.
Study: NCT06074640

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MET PIR with Dry Needling
Description: MET PIR Protocol: The subject will be asked to exert a small effort (20% of available strength) towards plantar flexion, against unyielding resistance, for 20 seconds. Once released, ankle will be dorsiflexed beyond the new range gained and stretched for up to 30 seconds. Rest period will be of 1 minute in between each repetition. (3 Repetitions, 1 Sets, 3 days per week, for 4 weeks consecutively.) MTrPs will be identified and located using flat or pincer palpation method in the Triceps Surae complex of the affected leg. The identified trigger points will be marked with a marker. Piston technique of dry needling is performed on the identified MTrPs in calf muscles. The self stretches of Plantar Fascia and Calf muscles will be demonstrated. The stretch position will be maintained for 20 sec, followed by 20 sec rest and then repeated for 3 minutes. All stretches will be performed twice daily by patients for 4 weeks time period (3 Reps, 2 sets/day, for 4 weeks)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MET PIR without Dry Needling
Description: MET PIR Protocol: The subject will be asked to exert a small effort (20% of available strength) towards plantar flexion, against unyielding resistance, for 20 seconds. Once released, ankle will be dorsiflexed beyond the new range gained and stretched for up to 30 seconds. Rest period will be of 1 minute in between each repetition. (3 Repetitions, 1 Sets, 3 days per week, for 4 weeks consecutively.) The self stretches of Plantar Fascia and Calf muscles will be demonstrated. The stretch position will be maintained for 20 sec, followed by 20 sec rest and then repeated for 3 minutes. All stretches will be performed twice daily by patients for 4 weeks time period (3 Reps, 2 sets/day, for 4 weeks)
Study: NCT06266754

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral polio vaccine
Description: Standard oral polio vaccine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline 0.9%
Study: NCT05318937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-718
Description: Softgel capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SAGE-718-matching placebo
Description: Softgel capsules
Study: NCT05085574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: 80 mg tablet, QID for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 400 mg (initial dose), then 200 mg capsule, BID for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet, QID for 14 days; capsule, BID for 5 days
Study: NCT05371730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NCR300
Description: Intravenous infusion of NK cells（NCR300）
Study: NCT06708429

Intervention type: DIAGNOSTIC_TEST
Intervention: LYNX EYE (Lynch syndrome X-Talk of Enteral mucosa with Immune System)
Description: A combination of blood-based, mucosal-based, and hair-based analyses that evaluate the presence and the expression of:~* a set of microRNAs (blood)~* antibodies anti-frame shift peptides (blood)~* mucosal-resident bacteria (healthy mucosa and cancer)~* environmental exposure to potential carcinogens (hair matrix)

Intervention type: DIAGNOSTIC_TEST
Intervention: LYNX EYE (Lynch syndrome X-Talk of Enteral mucosa with Immune System)
Description: A combination of blood-based, mucosal-based, and hair-based analyses that evaluate the presence and the expression of:~* a set of microRNAs (blood)~* antibodies anti-frame shift peptides (blood)~* mucosal-resident bacteria (healthy mucosa and cancer)~* environmental exposure to potential carcinogens (hair matrix)

Intervention type: DIAGNOSTIC_TEST
Intervention: LYNX EYE (Lynch syndrome X-Talk of Enteral mucosa with Immune System)
Description: A combination of blood-based, mucosal-based, and hair-based analyses that evaluate the presence and the expression of:~* a set of microRNAs (blood)~* antibodies anti-frame shift peptides (blood)~* mucosal-resident bacteria (healthy mucosa and cancer)~* environmental exposure to potential carcinogens (hair matrix)

Intervention type: DIAGNOSTIC_TEST
Intervention: LYNX EYE (Lynch syndrome X-Talk of Enteral mucosa with Immune System)
Description: A combination of blood-based, mucosal-based, and hair-based analyses that evaluate the presence and the expression of:~* a set of microRNAs (blood)~* antibodies anti-frame shift peptides (blood)~* mucosal-resident bacteria (healthy mucosa and cancer)~* environmental exposure to potential carcinogens (hair matrix)
Study: NCT06064149

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CARE-PC Web-Based Application
Description: The CARE-PC app is a pragmatic, patient-oriented, web-based application that enables the education of patients regarding cardiovascular (CV) risks and collects CV and prostate cancer-related risk variables and CV care access data from prostate cancer patients receiving ADT.
Study: NCT06325124

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscle energy technique
Description: They would be receiving treatment as follow:~Muscle energy technique of hamstring and gastro-soleus. Frequency: 10 reps 3 times/week for 4 consecutive weeks Intensity starting from 20% to 50% resistance across barrier provided by Physical therapist Conventional PT including 1-cervical isometric exercises 2-Transcutaneous Electrical Nerve Stimulation (TENS) for 1o minutes 3-hot pack for 10 minutes 4-Stretching exercise for suboccipitals, sternocleidomastoid 5-gentle stretching of calf and hamstrings.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional PT
Description: They would be receiving treatment as follow:~Conventional PT including 1-cervical isometric exercises 2-Transcutaneous Electrical Nerve Stimulation (TENS) for 1o minutes 3-hot pack for 10 minutes 4-Stretching exercise for suboccipitals, sternocleidomastoid 5-gentle stretching of calf and hamstrings.
Study: NCT06712745

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Personalized Ultra-fractionated stereotactic ablative radiotherapy (PULSAR)
Description: Radiation Therapy Prescription Dose: A dose of 40-50 Gy in 5 fractions prescribed to the PTV will be used for all cases
Study: NCT06714591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-M11D1
Description: The study includes 2 parts:~Part 1 Dose escalation. Part 2 Dose Finding non-randomized.
Study: NCT06713720

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning Device
Description: Participants in this group will use a remote ischemic conditioning device that applies five cycles of 5-minute inflation at 200 mmHg followed by 5-minute deflation on both arms, twice daily, for at least five days per week over one year. The device is designed to enhance retinal oxygenation and reduce hypoxia-related damage.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Remote Ischemic Conditioning Device
Description: Participants in this group will use the same remote ischemic conditioning device set to an inflation pressure of 60 mmHg to simulate the treatment. This placebo intervention follows the same timing and cycle frequency as the active intervention group.
Study: NCT04694703

Intervention type: DRUG
Intervention: Covid-19 group
Description: Routine COVID-19 treatment
Study: NCT06713811

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Description: Cureety is a digital telemonitoring platform specially designed to monitor cancer patients through self-reporting of adverse events. It supports patients and medical teams to complement existing care practices.
Study: NCT06713057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide+Pemetrexed+5-Fluorouracil
Description: IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide+Doxorubicin+5-Fluorouracil
Description: IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vindesine + Cisplatin
Description: IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin + Cisplatin
Description: IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin + Cyclophosphamide + Cisplatin
Description: IV or PO
Study: NCT05624762

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-Intensity Focused Ultrasound (LIFU)
Description: LIFU device (LCA200; Chongqing Haifu Medical Technology Co., Ltd., Chongqing, China).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Low-Intensity Focused Ultrasound
Description: Sham Low-Intensity Focused Ultrasound
Study: NCT06076135

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intestinal Low Dose Radiotherapy-1Gy
Description: 1Gy ILDR will be administered to patients in a single fraction. The radiation treatment volume composes both the jejunum and ileum.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intestinal Low Dose Radiotherapy-2-3Gy
Description: ILDR will be administered as single fractions within 10 days. The total dose of radiotherapy will be 2-3 Gy in 2-3 fractions. ILDR design is as above.
Study: NCT04848779

Intervention type: DRUG
Intervention: Alglucosidase alfa GZ419829
Description: Pharmaceutical form: Lyophilized powder for solution~Route of administration: intravenous
Study: NCT06076135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1/PD-L1 Inhibitors
Description: The immunotherapy regimen is the previous ICB therapy regimen or modified by the physician in charge. PD-1/PD-L1 inhibitors will be given 1 day after ILDR at a 3-week interval.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1/PD-L1 Inhibitors
Description: The immunotherapy regimen is the previous ICB therapy regimen or modified by the physician in charge. PD-1/PD-L1 inhibitors will be given 1 day after ILDR at a 3-week interval.
Study: NCT05498090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate 145 mg
Description: Fenofibrate 145 mg PO daily for 4 weeks
Study: NCT06077279

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Horticultural Therapy Program
Description: Horticultural Therapy Program Is selected plant therapy
Study: NCT06509984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast treatment
Description: treatment of apremilast
Study: NCT05703165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: animal-assisted intervention
Description: horse-assisted intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: animal-assisted intervention
Description: horse-assisted intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: watching the countryside
Description: just watching the countryside
Study: NCT05701631

Intervention type: DIAGNOSTIC_TEST
Intervention: Radiomic model
Description: Radiomic model for PCP diagnosis
Study: NCT05625867

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychological and quality of life questionnaires
Description: At 4/5 months and at 9 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological and quality of life questionnaires
Description: At 4/5 months and at 9 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interdisciplinary consultation at 4/5 months
Description: About ten days after the questionnaires were administered
Study: NCT05614219

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biochemistry interpretive comment on elevated LDL-C levels
Description: The interpretive comment on LDL-C will encourage for excluding secondary dyslipidemia (measuring Hba1C, TSH and checking current drugs and talk about diet). If secondary dyslipidemia ca be excluded we encourage to referral to lipid clinic. Familial hypercholesterolemia should be suspected if LDL-C \> 4 mmol/L in persons under the age of 40, or LDL-C \> 5 mmol/L in persons over the age of 40. The biochemistry interpretive comment will thus be released to the referring physician if the blood sample meet the criteria above. We advice that in pregnant women to control elevated LDL-C after childbirth.
Study: NCT06449391

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RAI
Description: Immediate implantation
Study: NCT05922709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS12192 capsule
Description: Participants receive CS12192 orally single or multiple doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS12192 capsule
Description: Participants receive CS12192 orally single or multiple doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS12192 capsule
Description: Participants receive CS12192 orally single or multiple doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS12192 capsule
Description: Participants receive CS12192 orally single or multiple doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS12192 capsule
Description: Participants receive CS12192 orally single or multiple doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS12192 capsule
Description: Participants receive CS12192 orally single or multiple doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS12192 capsule
Description: Participants receive CS12192 orally single or multiple doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS12192 capsule
Description: Participants receive CS12192 orally single or multiple doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS12192 capsule
Description: Participants receive CS12192 orally single or multiple doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS12192 capsule
Description: Participants receive CS12192 orally single or multiple doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Participants receive placebo matching CS12192 orally single or multiple doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Participants receive placebo matching CS12192 orally single or multiple doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Participants receive placebo matching CS12192 orally single or multiple doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Participants receive placebo matching CS12192 orally single or multiple doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Participants receive placebo matching CS12192 orally single or multiple doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Participants receive placebo matching CS12192 orally single or multiple doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Participants receive placebo matching CS12192 orally single or multiple doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Participants receive placebo matching CS12192 orally single or multiple doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Participants receive placebo matching CS12192 orally single or multiple doses
Study: NCT05296941

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brush sampling
Description: Brush sampling instead of surgical biopsy for control of reaccurance

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Brush sampling
Description: Brush sampling instead of surgical biopsy for control of reaccurance
Study: NCT05542849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose Tablets 50mg
Description: Acarbose is an Alpha-glucosidase inhibitor. It is a compound also known under the names Glucobay, Precose, and Prandase. Acarbose is used (with diet and other medications) to treat type 2 diabetes (condition in which the body does not use~insulin normally and therefore cannot control the amount of sugar in the blood). Acarbose works by blocking α- glucosidase, which breaks down starch (aka amylose) into glucose (sugar) into your blood. Slowing food digestion~helps keep blood glucose from rising very high after meals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose Tablets 50mg
Description: Acarbose is an Alpha-glucosidase inhibitor. It is a compound also known under the names Glucobay, Precose, and Prandase. Acarbose is used (with diet and other medications) to treat type 2 diabetes (condition in which the body does not use~insulin normally and therefore cannot control the amount of sugar in the blood). Acarbose works by blocking α- glucosidase, which breaks down starch (aka amylose) into glucose (sugar) into your blood. Slowing food digestion~helps keep blood glucose from rising very high after meals.
Study: NCT06210581

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised Exercise Program Group
Description: The exercise programs will performed with the physiotherapist. The treatment programs of the patients will start with warm-up exercises and continue with aerobic exercises. Strengthening exercises will be performed in lying, sitting and standing positions. Body weight or free weight will be used for strengthening exercises. Balance exercises will be performed in sitting and standing positions and will be performed with or without support according to the patients conditions. The treatment sessions will be terminated by performing relaxation exercises combined with stretching and breathing exercises.

Intervention type: OTHER
Group type: OTHER
Intervention: Internet Based Exercise Program Group
Description: Patients who are in the internet-based exercise program group will register cite ''https://www.telenororehab.com /'' which is web- based physiotherapy program for exercises. After the first evaluation patients will be given a username and password to log in to the system.~Before starting the exercise programs, the pages on how patients can log in to the system, how they can reach the physiotherapist through the system and how they can find individual exercise programs will be shown before the study. After logging in to their own pages, patients will be able to access video-based exercise programs that have been specially prepared for them. Patients in the Internet-based exercise program group will also be given the same exercise programs as the supervised exercise program group. The entry-exit times of patients to the system and the duration of maintaining exercise programs will be controlled from the administrator section on the system.
Study: NCT04288271

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence Intervention
Description: Intervention:~* Adherence Support Team (patient, parent or a significant other, Coach)~* Standardized educational videos on immunosuppressive medications, rejection, and improving adherence~* Identification of adherence barriers, self-efficacy for medication-taking, and allocation of treatment responsibility~* 'Action-Focused Problem-Solving' to address barriers selected as most important by the patient~Device:~* Electronic pillbox monitoring with text message and/or audio/visual dose reminders and access to e-pillbox website~* Feedback of electronic monitoring data at increasing intervals between initiation of the intervention at 4-week and exit at 14-week.

Intervention type: OTHER
Group type: OTHER
Intervention: Healthy living education intervention
Description: Intervention:~* Standardized educational videos on immunosuppressive medications, rejection, and improving adherence~* Healthy living topic discussion at increasing intervals between 4-wk and 14-wk visits~* 'Action-Focused Problem-Solving' to address barriers on healthy living topic selected by the patient~Device:~• Electronic adherence monitoring without dose reminders or feedback (enrollment to 14w)
Study: NCT05025254

Intervention type: OTHER
Intervention: Neurocognitive testing
Description: We are assessing several cognitive domains and have made minor adaptations (reducing the total number of trials or lengthening response windows) to several standard neuropsychology tests including measures of executive function, working memory, visuospatial function, declarative memory, reward processing, response inhibition.~Overall, the tests we use follow a standard set-up: participants are shown stimuli on the screen and are asked to provide a response using either a keyboard or a mouse, based on a specific set of instructions. We always provide a detailed set of on-screen instructions and a practice phase. In some cases, information about performance is provided in the form of points, in other cases, none is provided.

Intervention type: OTHER
Intervention: Neurocognitive testing
Description: We are assessing several cognitive domains and have made minor adaptations (reducing the total number of trials or lengthening response windows) to several standard neuropsychology tests including measures of executive function, working memory, visuospatial function, declarative memory, reward processing, response inhibition.~Overall, the tests we use follow a standard set-up: participants are shown stimuli on the screen and are asked to provide a response using either a keyboard or a mouse, based on a specific set of instructions. We always provide a detailed set of on-screen instructions and a practice phase. In some cases, information about performance is provided in the form of points, in other cases, none is provided.
Study: NCT05284877

Intervention type: OTHER
Intervention: No intervention
Description: The study is an observational study without intervention.

Intervention type: OTHER
Intervention: No intervention
Description: The study is an observational study without intervention.

Intervention type: OTHER
Intervention: No intervention
Description: The study is an observational study without intervention.
Study: NCT05530785

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: radiotherapy combined with sintilimab and bevacizumab biosimilar
Description: After signing informed consent, patients received sintilimab 200 mg intravenously on the first day of each cycle, Q3W; Bevacizumab biosimilar 7.5mg/kg was administered intravenously on the first day of each cycle, Q3W; Concurrent radiotherapy (single dose 3-8Gy, times 3-10, total dose 20-50Gy; The duration of radiotherapy was completed between the first administration of sintilimab and the second administration of bevacizumab, but it should be noted that the interval between before and after the administration of sintilimab and bevacizumab was at least 3 days.
Study: NCT06713057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel + Doxorubicin
Description: IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel + Carboplatin
Description: IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel + Doxorubicin
Description: IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel + Cisplatin
Description: IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine alone
Description: IV or PO